Molecular and traditional chemotherapy: a united front against prostate cancer

Cancer Letters
P SinghAparajita Khatri

Abstract

Castrate resistant prostate cancer (CRPC) is essentially incurable. Recently though, chemotherapy demonstrated a survival benefit ( approximately 2months) in the treatment of CRPC. While this was a landmark finding, suboptimal efficacy and systemic toxicities at the therapeutic doses warranted further development. Smart combination therapies, acting through multiple mechanisms to target the heterogeneous cell populations of PC and with potential for reduction in individual dosing, need to be developed. In that, targeted molecular chemotherapy has generated significant interest with the potential for localized treatment to generate systemic efficacy. This can be further enhanced through the use of oncolytic conditionally replicative adenoviruses (CRAds) to deliver molecular chemotherapy. The prospects of chemotherapy and molecular-chemotherapy as single and as components of combination therapies are discussed.

References

Jun 21, 1994·Proceedings of the National Academy of Sciences of the United States of America·J F EngelhardtJ M Wilson
Jan 1, 1993·The Prostate·A G CarrollE P Gelmann
Jan 1, 1993·Cancer Investigation·S M Freeman, J A Zwiebel
Jun 15, 2000·World Journal of Urology·K S KoenemanT A Gardner
Sep 19, 2000·Antimicrobial Agents and Chemotherapy·D ZhouJ T Dalton
Mar 10, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·A H DjehaC J Wrighton
Apr 26, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·M ChhikaraE Aguilar-Cordova
May 5, 2001·Pharmacology & Therapeutics·A BzowskaD Shugar
Aug 30, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T U KrohneL Mohr
Apr 19, 2002·Cancer Gene Therapy·Rosetta Martiniello-WilksPamela J Russell
Sep 17, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sang-Jin LeeChinghai Kao
Dec 24, 2002·Prostate Cancer and Prostatic Diseases·C H BangmaW Gerritsen
Jan 11, 2003·Cancer Gene Therapy·Susan Varghese, Samuel D Rabkin
Jan 11, 2003·Cancer Gene Therapy·Nicola K Green, Leonard W Seymour
Jan 13, 2004·The Journal of Gene Medicine·Rosetta Martiniello-WilksPamela J Russell

❮ Previous
Next ❯

Citations

Nov 8, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jinming HuangChun Yang
Mar 14, 2013·Molecular Oncology·Maxime Parisotto, Daniel Metzger
Mar 29, 2014·Journal of Computational Biology : a Journal of Computational Molecular Cell Biology·Nivit GillTrilok C Aseri
Apr 12, 2012·Macromolecular Bioscience·Jihua LiuJindřich Kopeček
May 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Preetiner Pal SinghAparajita Khatri
Aug 27, 2014·Bioorganic & Medicinal Chemistry Letters·Mikhail KrasavinAndrei A Gakh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Related Papers

Alzheimer's & Dementia : the Journal of the Alzheimer's Association
Alzheimer's Association
© 2021 Meta ULC. All rights reserved